Snaith et al. ([@B1]) suggest that the relationship between insulin dose and adverse cardiometabolic profile might be mediated by insulin resistance and cite data linking clamp-derived measurement of insulin resistance and coronary artery calcification ([@B2]). We do not have any direct assessment of insulin resistance in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study; however, the association among weight gain, insulin resistance, and adverse cardiometabolic risk factors is well known and was discussed in our article ([@B3]). Insulin-mediated downregulation (via degradation) of insulin receptors certainly occurs and could be one of numerous receptor and postreceptor mechanisms underlying insulin resistance ([@B4]). Snaith et al. further suggest that improving insulin sensitivity in type 1 diabetes could improve cardiovascular risk, in support of which they cited the Reducing with Metformin Vascular Adverse Lesions (REMOVAL) study ([@B5]) on the effect of metformin on carotid intima-media thickness (cIMT). Notably, the REMOVAL study did not find a significant effect of metformin on the primary outcome of progression of cIMT, thus the significance of the finding regarding maximal cIMT (a tertiary end point) is unclear.
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